Abbvie Inc.

Zoetis Belgium S.a

Abbvie Deutschland Gmbh and Co Kg

Mary Leddy

Chung-Ming Hsieh

Eve H Barlow

Jennifer Maria Perez

Yuliya Kutskova

John Memmott

Anca Clabbers

Anwar Murtaza

Suju Zhong

Margaret Hugunin

Edit Tarcsa

Bradford L McRae

Craig Wallace

Shaughn H Bryant

Charles W Hutchins

Ravi Chari

Emma Fung

Susan E Lacy

Meha Chhaya

Diane M Lang

Jeffrey A Barbon

Bernhard K Mueller

Martin Schmidt

Philip D Bardwell

Susan E Lacey

The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.

Caninized anti-NGF antibodies and their use

Anti-NGF antibodies and their use

Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

IL-17 binding proteins

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

Antibodies against the RGM a protein and uses thereof

Proteins that bind IL-17 and/or IL-17F are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Antibodies against the RGM A protein and uses thereof

Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Growing community of inventors

North Attleboro, MA, United States of America

Mary Leddy